Category: Congress Info

The Targeting Phage Therapy 2023 Best Scientific Contribution award was discerned to: Amanda (Curtis) Burkardt, CEO of PHIOGEN, USA Ms. Burkardt was awarded for creating patient ready products in a remedy ready world. Spun-off from of one of the US’s only phage therapy cores, TAILOR Labs at Baylor College of Medicine, an ambitious new biotech…

25+ posters will be presented during Targeting Phage Therapy 2023 on June 1-2.  Access the full list of posters.

Iddo Nadav Weiner, VP of Research at BiomX, Israel presented a short oral talk entitled “A Phase 1b/2a Randomized, Double-blind, Placebo-controlled Study Evaluating Nebulized Phage Therapy in Cystic Fibrosis Subjects With Chronic Pseudomonas Aeruginosa Pulmonary Infection ” during Targeting Phage Therapy 2023 on June 1-2 in Paris. Dr. Weiner will describe the development of a…

Adam Ostrowski, Cellexus, United Kingdom presented a short oral talk entitled “Implementing GMP Manufacturing for Phage Therapy” during Targeting Phage Therapy 2023 on June 1-2 in Paris. The CellMaker single use, airlift bioreactor is an ideal fermentation system for phage production in a GMP environment. The patented airlift technology provides excellent mixing and aeration kinetics…

Targeting Phage 2023: Questions, Controversies, & What is Next? Targeting Phage Therapy 2023 will highlight the recent innovations and clinical applications of phages, validation and limitations. Targeting Phage Therapy 2023 will also cover how phages will transform the medicine of tomorrow. More Than Just Scientific Knowledge at Targeting Phage Therapy 2023: The regulation and legal…